Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $141.46 USD
Change Today -0.09 / -0.06%
Volume 488.5K
BDX On Other Exchanges
New York
As of 2:07 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $149.98
52 Week Low
09/22/14 - $112.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Life Sciences segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. It also offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. In addition, the company develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. Becton, Dickinson and Company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Executive Vice President and President of Glo...
Total Annual Compensation: $605.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $900.8K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Declares Quarterly Dividend Payable on June 30, 2015

Becton, Dickinson and Company has declared a quarterly dividend of 60.0 cents per common share payable on June 30, 2015 to holders of record on June 9, 2015. The indicated annual dividend rate is $2.40 per share.

BD Medical Receives FDA Clearance for Novel Infusion Set with BD FlowSmart Technology

BD Medical, a segment of BD (Becton, Dickinson and Company) announced it has received 510(k) clearance from the U.S. Food and Drug Administration for a new insulin infusion set with BD FlowSmart technology. Insulin infusion sets connect the insulin pump to the body. The new product is BD's first within the diabetes infusion set category. BD FlowSmart features a unique side-ported catheter designed to improve insulin flow, potentially reducing the number of flow interruptions - defined as a continuous rise in pressure lasting at least 30 minutes. Without triggering an occlusion alarm, these events are known as silent occlusions, which could lead to unexplained hyperglycemia in some patientsi,ii. This infusion set also features the smallest insertion needle, designed to reduce insertion pain and trauma. The product is expected to launch in the U.S. in fiscal year 2016. BD collaborated with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust on the research and development of the new infusion set to enhance the use of insulin pumps and improve the treatment of type 1 diabetes. Approximately two thirds of current insulin pump users have been shown to experience insulin flow interruptions that often go undetected by the pump occlusion alarm system.

Becton, Dickinson and Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015; Reaffirms Earnings Guidance for the Year 2015

Becton, Dickinson and Company reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported revenues of USD 2,051 million compared to USD 2,072 million a year ago. Operating income was USD 293 million compared to USD 381 million a year ago. Income before income taxes was USD 225 million compared to USD 363 million a year ago. Net income was USD 216 million compared to USD 287 million a year ago. Diluted earnings per share were USD 1.08 compared to USD 1.45 million a year ago. Adjusted diluted earnings per share were USD 1.61, compared with USD 1.59 in the prior-year period. This represents an increase of 1.3%, or 8.2% on a currency-neutral basis. For the six months, the company reported revenues of USD 4.102 million compared to USD 4.086 million a year ago. Operating income was USD 642 million compared to USD 759 million a year ago. Income before income taxes was USD 510 million compared to USD 722 million a year ago. Net income was USD 452 million compared to USD 558 million a year ago. Diluted earnings per share were USD 2.28 compared to USD 2.82 million a year ago. For the six-month period ended March 31, 2015, adjusted diluted earnings per share were USD 3.14, compared with USD 3.02 in the prior-year period. This represents an increase of 4.0%, or 11.6% on a currency-neutral basis. The company reaffirms its previously communicated currency-neutral revenue and earnings guidance on a standalone basis. The company expects full fiscal year 2015 adjusted diluted earnings per share, including the accretion from the CareFusion acquisition, to be between USD 7.00 and USD 7.10. This represents growth of 19.0% to 20.0% on a currency-neutral basis. Including the estimated unfavorable impact of foreign currency, the Company expects adjusted diluted earnings per share growth of 8.0% to 9.0%. The company expects full fiscal year reported diluted earnings per share to be between USD 4.20 and USD 4.30. Reaffirms that the acquisition of CareFusion is expected to be accretive to adjusted diluted earnings per share on a high-teen percentage basis in fiscal year 2016. The Company estimates that revenues for the full fiscal year 2015 will increase approximately 5.0% on a foreign currency-neutral basis. On a reported basis, revenues are expected to decline approximately 1.5%, due to the unfavorable impact of foreign currency. The company expects adjusted diluted earnings per share to grow 9.0% to 10.0% on a foreign currency-neutral basis. Including the estimated unfavorable impact of foreign-currency, adjusted diluted earnings per share are expected to be between USD 6.43 and USD 6.50. The company expects revenue growth for NewCo to be 28% to 29% with BD Medical growing at 48% to 49% and Life Sciences growing at about 5%. Gross profit as a percentage of revenue is expected to be approximately 52% to 52.5%. The company expected tax rate to be between 23% and 24%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $141.46 USD -0.09

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,820 JPY +4.00
Avago Technologies Ltd $140.37 USD -1.12
Boston Scientific Corp $18.41 USD +0.42
Mylan NV $72.79 USD +0.75
Stryker Corp $96.07 USD -0.52
View Industry Companies

Industry Analysis


Industry Average

Valuation BDX Industry Range
Price/Earnings 25.7x
Price/Sales 3.3x
Price/Book 4.1x
Price/Cash Flow 27.2x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at